If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  90Y Radioembolisation Provides Benefit for Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy: Presented at ESMO-GI By Jenny Powers BARCELONA, Spain -- July 2, 2009 -- 90Y radioembolisation provides substantial clinical benefit to patients with colorectal cancer (CRC) liver metastases who have failed multiple lines of systemic chemotherapy, researchers stated here at the 11th World Gastrointestinal Cancer Congress of the European Society for Medical Oncology (ESMO-GI). Lead investigator Jens Ricke, MD, Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany, presented the results of a study on June 26 that may offer possible treatment to patients whose CRC metastases have progressed despite previous systemic chemotherapy. Of the patients, 29 received 90Y-resin microsphere therapy and 29 controls received best supportive care and/or chemotherapy. Patients in the 90Y-radioembolisation arm had received a median of 4 (range, 2-7) lines of chemotherapy and controls had received a median of 3 (range, 2-8). Not receiving 90Y-microsphere therapy (hazard ratio = 4.0) was the only significant contributor to the prognosis for overall survival (OS) of patients failing standard-of-care chemotherapy (P < .001). This study was a matched-pair analysis with a primary endpoint of OS. Patients who received 90Y-microsphere therapy had significantly prolonged survival compared with control patients (median survival: 8.3 vs 3.5 months; P < .001). At 3 months post treatment, patient survival was 97% in the 90Y-microsphere group versus 59% in the control group. This effect was sustained through the 12-month follow up, where 24% of 90Y-microsphere-treated patients were alive; no control patients were alive at this time point. Tumour stabilisation was seen in patients who received 90Y-microsphere therapy compared with controls (median PFS was 5.5 vs 2.1 months, respectively; P < .001). Adverse events included 1 case of thrombopenia and 1 case of sepsis, 1 case of abdominal pain, and 3 possible cases of radiation-induced liver disease (RILD) following 90Y-microsphere therapy. RILD was medically managed and not a life-threatening event. The investigators concluded that 90Y-microsphere therapy provides treatment possibilities for patients who have failed multiple lines of systemic chemotherapy and whose liver-dominant disease is the life-limiting condition. [Presentation title: Extensive Liver-Dominant Colorectal (CRC) Metastases Failing Multiple Lines of Systemic Chemotherapy Treated by 90Y Radioembolisation: A Matched-Pair Analysis. Abstract O-002]
|
